Short QT Syndrome

Overview

Journal CMAJ

Date 2005 Nov 23

PMID 16301704

Citations 18

Authors

Ramon Brugada

Kui Hong

Jonathan M Cordeiro

Robert Dumaine

Affiliations

Soon will be listed here.

Abstract

The QT interval on an electrocardiogram signifies the time required for the heart to repolarize after depolarization. It has long been appreciated that a long QT interval predisposes patients to life-threatening ventricular arrhythmia. Short QT syndrome is a newly described disease characterized by a shortened QT interval and by episodes of syncope, paroxysmal atrial fibrillation or life-threatening cardiac arrhythmias. The syndrome usually affects young and healthy people with no structural heart disease and may be present in sporadic cases as well as in families. Our understanding of a new disease has rarely benefitted so quickly from research in genetics, molecular biology and biophysics. It was first described in 2000 in a handful of patients, and since then 3 different genes associated with the disease and the biophysical basis have been described, and therapy has been made available. Here we review the current understanding of the pathophysiology, clinical presentation and treatment of short QT syndrome.

Citing Articles

Efficacy of prescribing Inderal for polymorphic ventricular tachycardia in a young patient with the normal QT interval: A case report study.

Shafiee M, Nassari Z, Baharlouei-Yancheshmeh F, Tahery N, Baradaran A, Tabahfar R SAGE Open Med Case Rep. 2024; 12:2050313X241272538.

PMID: 39224760 PMC: 11367602. DOI: 10.1177/2050313X241272538.

CineECG analysis provides new insights into Familial ST-segment Depression Syndrome.

Frosted R, Paludan-Muller C, Bundgaard Vad O, Olesen M, Bundgaard H, van Dam P Europace. 2023; 25(5).

PMID: 37140072 PMC: 10228618. DOI: 10.1093/europace/euad116.

Overlap Arrhythmia Syndromes Resulting from Multiple Genetic Variations Studied in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Treat J, Pfeiffer R, Barajas-Martinez H, Goodrow R, Bot C, Haedo R Int J Mol Sci. 2021; 22(13).

PMID: 34281161 PMC: 8268422. DOI: 10.3390/ijms22137108.

Successful radiofrequency catheter ablation of a premature ventricular contraction triggering ventricular fibrillation in a patient with short QT syndrome.

Morimoto Y, Watanabe A, Morita H, Nishii N, Nakamura K, Ito H HeartRhythm Case Rep. 2019; 5(5):262-265.

PMID: 31193207 PMC: 6522426. DOI: 10.1016/j.hrcr.2019.01.012.

Styrax blocks inward and outward current of Kir2.1 channel.

Ren S, Pang C, Li J, Huang Y, Zhang S, Zhan Y Channels (Austin). 2016; 11(1):46-54.

PMID: 27540685 PMC: 5279881. DOI: 10.1080/19336950.2016.1207022.

References

Priori S, Pandit S, Rivolta I, Berenfeld O, Ronchetti E, Dhamoon A . A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res. 2005; 96(7):800-7. DOI: 10.1161/01.RES.0000162101.76263.8c. View

Cordeiro J, Brugada R, Wu Y, Hong K, Dumaine R . Modulation of I(Kr) inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome. Cardiovasc Res. 2005; 67(3):498-509. DOI: 10.1016/j.cardiores.2005.02.018. View

Hong K, Piper D, Diaz-Valdecantos A, Brugada J, Oliva A, Burashnikov E . De novo KCNQ1 mutation responsible for atrial fibrillation and short QT syndrome in utero. Cardiovasc Res. 2005; 68(3):433-40. DOI: 10.1016/j.cardiores.2005.06.023. View

Hong K, Bjerregaard P, Gussak I, Brugada R . Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J Cardiovasc Electrophysiol. 2005; 16(4):394-6. DOI: 10.1046/j.1540-8167.2005.40621.x. View

Schulze-Bahr E, Breithardt G . Short QT interval and short QT syndromes. J Cardiovasc Electrophysiol. 2005; 16(4):397-8. DOI: 10.1046/j.1540-8167.2005.40799.x. View

Wolpert C, Schimpf R, Giustetto C, Antzelevitch C, Cordeiro J, Dumaine R . Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005; 16(1):54-8. PMC: 1474841. DOI: 10.1046/j.1540-8167.2005.04470.x. View

Lees-Miller J, Duan Y, Teng G, Duff H . Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol Pharmacol. 2000; 57(2):367-74. View

Gussak I, Brugada P, Brugada J, Wright R, Kopecky S, Chaitman B . Idiopathic short QT interval: a new clinical syndrome?. Cardiology. 2001; 94(2):99-102. DOI: 10.1159/000047299. View

Marban E . Cardiac channelopathies. Nature. 2002; 415(6868):213-8. DOI: 10.1038/415213a. View

10.

Volberg W, Koci B, Su W, Lin J, Zhou J . Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J Pharmacol Exp Ther. 2002; 302(1):320-7. DOI: 10.1124/jpet.302.1.320. View

11.

Gaita F, Giustetto C, Bianchi F, Wolpert C, Schimpf R, Riccardi R . Short QT Syndrome: a familial cause of sudden death. Circulation. 2003; 108(8):965-70. DOI: 10.1161/01.CIR.0000085071.28695.C4. View

12.

Schimpf R, Wolpert C, Bianchi F, Giustetto C, Gaita F, Bauersfeld U . Congenital short QT syndrome and implantable cardioverter defibrillator treatment: inherent risk for inappropriate shock delivery. J Cardiovasc Electrophysiol. 2003; 14(12):1273-7. DOI: 10.1046/j.1540-8167.2003.03278.x. View

13.

Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M . Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation. 2003; 109(1):30-5. DOI: 10.1161/01.CIR.0000109482.92774.3A. View

14.

Gaita F, Giustetto C, Bianchi F, Schimpf R, Haissaguerre M, Calo L . Short QT syndrome: pharmacological treatment. J Am Coll Cardiol. 2004; 43(8):1494-9. DOI: 10.1016/j.jacc.2004.02.034. View

15.

Bellocq C, van Ginneken A, Bezzina C, Alders M, Escande D, Mannens M . Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation. 2004; 109(20):2394-7. DOI: 10.1161/01.CIR.0000130409.72142.FE. View

16.

Commerford P, Lloyd E . Arrhythmias in patients with drug toxicity, electrolyte, and endocrine disturbances. Med Clin North Am. 1984; 68(5):1051-78. DOI: 10.1016/s0025-7125(16)31086-0. View

17.

Sanguinetti M, Jurkiewicz N . Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol. 1990; 96(1):195-215. PMC: 2228985. DOI: 10.1085/jgp.96.1.195. View

18.

Komeichi K, Tohse N, Nakaya H, Shimizu M, Zhu M, Kanno M . Effects of N-acetylprocainamide and sotalol on ion currents in isolated guinea-pig ventricular myocytes. Eur J Pharmacol. 1990; 187(3):313-22. DOI: 10.1016/0014-2999(90)90358-d. View

19.

Wettwer E, Grundke M, Ravens U . Differential effects of the new class III antiarrhythmic agents almokalant, E-4031 and D-sotalol, and of quinidine, on delayed rectifier currents in guinea pig ventricular myocytes. Cardiovasc Res. 1992; 26(11):1145-52. DOI: 10.1093/cvr/26.11.1145. View

20.

Roy M, Dumaine R, Brown A . HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation. 1996; 94(4):817-23. DOI: 10.1161/01.cir.94.4.817. View